Zobrazeno 1 - 10
of 610
pro vyhledávání: '"Masatoshi ETO"'
Autor:
Masaki Shiota, Shota Nemoto, Ryo Ikegami, Shuichi Tatarano, Toshiyuki Kamoto, Keita Kobayashi, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Akira Yokomizo, Seiji Naito, Masatoshi Eto
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background The predictive power of the treatment efficacy and prognosis in primary androgen deprivation therapy (ADT) for advanced prostate cancer is not satisfactory. The objective of this study was to integrate genetic and clinical data to
Externí odkaz:
https://doaj.org/article/db4199766c0a496080e9b53340cb9acc
Autor:
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Externí odkaz:
https://doaj.org/article/3d4ee96893544a25bb56c9e784f1f819
Autor:
Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6902-6912 (2023)
Abstract Background The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untrea
Externí odkaz:
https://doaj.org/article/8c1591921a074d1ba5b9e9d36660eacf
Autor:
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence
Externí odkaz:
https://doaj.org/article/09be4e69130a41858b234cdb2b5887cc
Autor:
Kazuo Nishimura, Masaki Shiota, Masatoshi Eto, Takefumi Satoh, Angela Stroupe, Caroline Seo, Alyssa Uzumcu, Dianne Athene Ledesma
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1762-1778 (2023)
Abstract Objective The study objectives were to understand how patients view the quality of life in non‐metastatic castration‐resistant prostate cancer (nmCRPC), including unmet needs and what patients consider most important in treatment outcome
Externí odkaz:
https://doaj.org/article/ae7388ed8d524f5ab7346936e1ff703e
Autor:
Leandro Blas, Masaki Shiota, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto
Publikováno v:
Asian Journal of Urology, Vol 10, Iss 1, Pp 81-88 (2023)
Objective: There are many models to predict extracapsular extension (ECE) in patients with prostate cancer. We aimed to externally validate several models in a Japanese cohort. Methods: We included patients treated with robotic-assisted radical prost
Externí odkaz:
https://doaj.org/article/413df8fe86c246838d5aa77174dc0391
Autor:
Taigo Kato, Nobuaki Matsubara, Masaki Shiota, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Yota Yasumizu, Nobuyuki Tanaka, Mototsugu Oya, Koshiro Nishimoto, Takuji Hayashi, Masashi Nakayama, Takahiro Kojima, Kenjiro Namikawa, Takao Fujisawa, Susumu Okano, Eisuke Hida, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Norio Nonomura
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Previous clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients with cancer involving homologous recombination repair (HRR) gene-mutation. Moreover, HRR gene
Externí odkaz:
https://doaj.org/article/5f0dc8735dd54b21bcb309ee64c3e011
Autor:
Kazuhiro Kai, Toshifumi Fujiwara, Yoshihiro Nagao, Eiji Oki, Tomoharu Yoshizumi, Masatoshi Eto, Yasuharu Nakashima
Publikováno v:
Bone Reports, Vol 18, Iss , Pp 101661- (2023)
Introduction: Sleeve gastrectomy is the most common surgical procedure to reduce weight and treat metabolic complications in patients with moderate-to-severe obesity; however, it affects the musculoskeletal system. Dual-energy X-ray absorptiometry (D
Externí odkaz:
https://doaj.org/article/528f30245e154d82b58991f82fbadfe2
Autor:
Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C. Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Chemotherapy is a standard therapy for muscle-invasive bladder cancer (MIBC). However, genomic alterations associated with chemotherapy sensitivity in MIBC have not been fully explored. This study aimed to investigate the genomic landscape o
Externí odkaz:
https://doaj.org/article/592f640d5f66404789c46f9398fa543d
Autor:
Shigetomo Yamada, Masaki Shiota, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Publikováno v:
Prostate International, Vol 10, Iss 1, Pp 50-55 (2022)
Background: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide have been shown to prolong survival in patients with advanced prostate cancer. However, there is limited evidence on the anticancer effect of a reduced dose
Externí odkaz:
https://doaj.org/article/bf0c9b5ed77f474e89a68a8d22bbbe84